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Limited Brain Metabolism Changes Differentiate
between the Progression and Clearance of Rabies Virus
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Abstract
Central nervous system (CNS) metabolic profiles were examined from rabies virus (RABV)-infected mice that were either
mock-treated or received post-exposure treatment (PET) with a single dose of the live recombinant RABV vaccine TriGAS.
CNS tissue harvested from mock-treated mice at middle and late stage infection revealed numerous changes in energy
metabolites, neurotransmitters and stress hormones that correlated with replication levels of viral RNA. Although the large
majority of these metabolic changes were completely absent in the brains of TriGAS-treated mice most likely due to the
strong reduction in virus spread, TriGAS treatment resulted in the up-regulation of the expression of carnitine and several
acylcarnitines, suggesting that these compounds are neuroprotective. The most striking change seen in mock-treated RABVinfected mice was a dramatic increase in brain and serum corticosterone levels, with the later becoming elevated before
clinical signs or loss of body weight occurred. We speculate that the rise in corticosterone is part of a strategy of RABV to
block the induction of immune responses that would otherwise interfere with its spread. In support of this concept, we
show that pharmacological intervention to inhibit corticosterone biosynthesis, in the absence of vaccine treatment,
significantly reduces the pathogenicity of RABV. Our results suggest that widespread metabolic changes, including
hypothalamic-pituitary-adrenal axis activation, contribute to the pathogenesis of RABV and that preventing these
alterations early in infection with PET or pharmacological blockade helps protect brain homeostasis, thereby reducing
disease mortality.
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11]. TriGAS is capable of inducing both the immune mechanisms
and effectors that promote their infiltration into CNS tissues
resulting in containment and clearance of a pathogenic RABV
CNS infection [10]. However, the mechanisms underlying rabies
pathogenesis as well as host responses that are able to restrict and
eventually clear the infection are likely complex and not fully
understood. Notably, infection of the CNS with wild-type (WT)
RABV does not result in neuronal loss or overt neuronal damage
[12–14]. Nonetheless, a significant factor responsible for the lethal
outcome of an RABV infection appears to be neuronal
dysfunction due to drastically inhibited synthesis of proteins
required in maintaining basic cellular and metabolic functions
[15]. Another characteristic of rabies is the limited immune cell
infiltration into the CNS tissues seen in human patients and
rodents infected with pathogenic RABV, which led to the concept
that RABV has the ability to evade immune clearance [16,17].
To obtain further insight into mechanisms involved in RABV
pathogenesis and the host responses that can prevent the lethal
outcome of the infection, we recently compared the transcriptomes
of uninfected mouse brain with those of WT RABV-infected mice
that had received either mock treatment or TriGAS PET. This
analysis showed that genes that play key roles in adaptive
immunity (e.g. Ccl3, IL12B, GzmA) are activated earlier and to
a greater extent in RABV-infected, TriGAS-treated mouse brains
versus RABV-infected, mock treated brains suggesting that timely

Introduction
Rabies is a central nervous system (CNS) disease caused by
infection with rabies virus (RABV), a negative-stranded RNA virus
of the Rhabdoviridae family. Despite the fact that rabies is one of the
oldest known infectious diseases, it continues to present a
veterinary and public health threat worldwide. Each year, more
than 70,000 humans die from rabies around the globe with
millions more undergoing post-exposure prophylaxis [1]. Rabies is
a zoonotic disease and carnivores, especially dogs, are the main
carriers of the virus [2–4]. RABV is usually transmitted via the bite
of an infected animal. It is commonly understood that the virus
travels from the site of exposure (e.g. open wound) through
retrograde axonal transport into the CNS [5–7]. Once humans
have developed clinical rabies there is currently no approved
treatment owing to features of the infection that allow wild-type
RABV to evade immune clearance from the CNS [7,8]. Recently,
live, highly attenuated rabies virus vaccines have been developed
and shown to be efficacious in rabies post-exposure treatment of
(PET) animal models [9]. The recombinant RABV TriGAS is one
such promising vaccine candidate, with an excellent pre- and postexposure therapy profile. It is highly immunogenic and nonpathogenic for mice that are either developmentally immunocompromised or have inherited deficits in immune function as well as
normal adult animals even when administered intracranially [9–
PLOS ONE | www.plosone.org

1

April 2014 | Volume 9 | Issue 4 | e87180

Metabolic Changes in Rabies Virus Pathogenesis

activation of these genes during the infection is likely an important
part of the mechanism by which TriGAS mediates its protective
activity [10]. However, the conclusions that can be drawn from
transcriptome analyses are limited since mRNA expression data
does not reveal the numerous biochemical processes in the brain
that are likely altered during the course of infection. There is now
growing evidence that metabolic profiling of living systems can
provide meaningful information about perturbations of metabolism caused by genetic deficits, aging or exogenous factors thought
to occur in different disease processes [18,19]. Hence, we utilized
metabolomics to characterize brain metabolism associated with
rabies infection and post-infection viral clearance facilitated by
TriGAS vaccine treatment. This analysis revealed significant
changes in biochemicals associated with energy metabolism in
infected, mock treated mice that were largely prevented with
vaccine treatment. Mitigation of changes in neurotransmitters and
stress hormones due to vaccine treatment may be predictive of
successful post-exposure therapy and, additionally, suggest new
possibilities for therapeutic intervention. In support of this
concept, we show that pharmacological intervention to inhibit
corticosterone biosynthesis, in the absence of vaccine treatment,
significantly reduces the pathogenicity of wild-type RABV strain
DOG4.

Results
PET with TriGAS reduces virus load and inhibits viral
spread in the CNS of mice infected with DOG4 RABV
To correlate changes in brain metabolites with RABV infection
of the brain, we first utilized RT-qPCR analysis to determine the
transcription levels of DOG4 RNA in the CNS of mock- and
TriGAS-treated DOG4-infected mice at 4, 6, and 8 days post
inoculation (p.i.). As shown in Figure 1A–C, DOG4 RABVspecific RNA is detected in whole brain, olfactory bulb and
hypothalamus of mock and TriGAS-treated mice at 4 days after
infection, although normalized DOG4 RNA copies were significantly lower in the brain regions of vaccine-treated mice (0.98,
7.34, and 0.22 copies in mock-treated group vs. 0.03, 0.56, 0.01
copies in vaccine-treated group; p,.05 each region, respectively).
By 6 days p.i, DOG4 RNA levels increased in the respective brain
tissues of both groups of mice, although levels in whole brain,
olfactory bulb, and hypothalamus were significantly lower in
vaccine versus mock-treated animals (30, 46, 43 copies vaccine vs.
157, 669, 442 copies mock; p,.01 each region). Importantly,
while DOG4 RNA levels in all brain regions of mock-treated
animals dramatically increased at day 8 p.i, they declined
significantly at this time in TriGAS-treated mice (583, 5358,
18252 copies mock vs. 2.9, 1.9, 8.5 copies vaccinated; p,.001
each region).

Figure 1. Post-exposure treatment of DOG4 RABV-infected
mice with TriGAS dramatically reduces the accumulation of
RABV N protein mRNA in the brain. Mice were infected i.n. with 105
FFU of DOG4 RV and 4 hr later either mock treated with PBS or treated
with 107 FFU of TriGAS. Ten to 15 mice per group were euthanized for
each tissue at each indicated time point, and the number of DOG4
RABV N mRNA copies in A) whole brain, B) olfactory bulb and C)
hypothalamus was quantified by qRT-PCR as described in Materials and
Methods. The results are presented as the mean RABV N mRNA copy
numbers (+SE) per 1,000 copies of L13 mRNA. The bars indicate
significant differences in copy numbers between mock-treated and PETtreated animals. *p,.05, **p,.01 and ***p,.001, respectively.
doi:10.1371/journal.pone.0087180.g001

Changes in levels of brain metabolites associated with
progression or inhibition of RABV infection
After cardiac perfusion and placement of each brain in
methanol, a total of 259 named biochemicals were analyzed in
CNS samples of 1) uninfected, untreated control, 2) infected,
mock-treated, and 3) infected, vaccine-treated animals taken at 0,
4, 6, and 8 days post-infection (p.i.) using liquid chromatography/
mass spectrometry (Table 1). Following log transformation and
imputation with minimum observed values for each compound,
Welch’s two-sample t-test was used to identify biochemicals that
differed significantly between experimental groups. A summary of
the number of changes in the levels of biochemicals that achieved
statistical significance (p#0.05), as well as those approaching
significance (0.05,p,0.1) is shown in Table 1.
PLOS ONE | www.plosone.org

The majority of alterations in brain metabolism occur late
in infection
While the results of the metabolome analysis demonstrated a
limited number of differences between vaccine and mock-treated
mice infected with RABV at days 4 and 6 post infection, there were
a much larger number of statistically significant changes at day 8.
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Principal Component Analysis (PCA) was used to investigate
associations between metabolite levels and infection/treatment.
This approach transforms a large number of metabolic variables
into a smaller number of orthogonal variables (PC1, PC2, PC3,
etc.), represented as symbols on a plot, that allow differences
between separate conditions to be assessed based on clustering.
Using such an approach, we found that biochemicals tended to
cluster together according to time and treatment with the exception
of the day 8 samples (Figure S1), which differed dramatically
between the three groups. While the number of statistically
significant changes was low prior to the day 6 time point (Table 1),
at day 8 p.i. vaccine and mock treatment resulted in a multitude of
changes as shown in the heat map (Table S1) and the PCA plot
(Figure S1), which distinguishes the results at this time point from
those of the earlier time points. The largest differences between
vaccine and mock treatment during the course of the study were
seen in the levels of acetylcholine (Ach), energy metabolites,
carnitines and carnitine-related metabolites, and corticosterone.

Summarized is the number of metabolites significantly altered during early (D4), middle (D6) and late-stage WT RABV infection (D8) with or without vaccine as well as the amount of those that approach significance.
doi:10.1371/journal.pone.0087180.t001
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Day 4
Days post infection

Vaccine Treatment vs. Mock Treatment
Vaccine Treatment vs. Uninfected Control
Mock Treatment vs. Uninfected Control.
Significantly Altered Biochemicals
(Welch’s Two Sample t Test)

Table 1. Significantly altered biochemicals during the course of WT RABV infection in the presence or absence of PET with TriGAS.
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PET with TriGAS prevents the infection-induced
reduction in Ach levels
We found Ach to be significantly lower at days 6 and 8 postinfection in the CNS tissues of mice that received mock treatment
by comparison with similarly infected mice that received vaccine
(Figure 2). There was an increase in the disparity between the two
groups over time (15.1+/27.1% D4, 15.8+/23.7% D6, &
19.5%+/25.5%). Furthermore, there were also significant differences in Ach levels between the mock-treated and uninfected,
untreated animals at D4 and D8 p.i, p,.05. However, no
significant differences in acetylcholine levels were detected
between the CNS tissues of normal versus DOG4/TriGAStreated animals. The declining Ach levels during the course of
RABV infection likely result in progressively impaired cholinergic
neurotransmission [20,21].

RABV infection elevates brain energy metabolites
Pathogenic RABV-infected, mock-treated animals displayed
significantly higher levels of the ketone body 3-hydroxybutyrate
(BHBA) at day 8 in relation to the vaccine-treated samples in this
study (Figure 3A), p,.05. Notably, mock-treated animals also
exhibited a 123+/236% increase in BHBA in relation to uninfected
controls at this time (p,.01). Furthermore, there was a significant
increase in glucose levels in mock-treated mice in relation to vaccine
treated RABV-infected mice at day 6 (Figure 3B), p,.05, with
mock-treated animals also displaying a significant increase over
uninfected, untreated controls at this time (p,.01). The increase in
both of these energy-associated metabolites in the brain tissue of
mock-treated mice may be an indication of decreased glucose
utilization or increased glucose uptake by the brain.

Carnitine and carnitine-related metabolites are increased
by vaccine treatment
One interesting finding in this study was that carnitine and a
number of acylcarnitines (hexanoylcarnitine, octanoylcarnitine,
laurylcarnitine, palmitoylcarnitine, stearoylcarnitine, oleoylcarnitine and butyrylcarnitine), were significantly higher at day 8 p.i. in
the brains of vaccine-treated mice in relation to either the
uninfected controls or mock-treated mice (Figure 4A–H), (*p,.05
- *** p,.001). The increase in carnitine levels could be one of the
mechanisms by which TriGAS exerts its protective activity against
a lethal RABV infection. These biochemicals have been shown to
be protective in animal models of ischemia, neurodegeneration
and viral-induced encephalitis [22,23].
3
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Figure 2. PET with TriGAS prevents the RABV infectioninduced decline in acetylcholine. Mice were infected i.n. with 105
FFU of DOG4 and 4 hr later either mock treated i.m. with PBS or treated
with 107 FFU of TriGAS. An additional group of uninfected, untreated
mice served as a reference. Six mice per group were euthanized for
each time point, and the levels of acetylcholine were determined via LCGC/MS-MS2 as described in Materials and Methods. The results are
presented as comparative levels (+/2 SE). Statistical differences
between groups were analyzed using Welch’s two sample t test and
are identified by *p,0.05. The horizontal lines represent significant
differences between control and DOG4-infected/mock-treated mice
while the asterisks over bars represent differences between mock- and
TriGAS –treated, infected mice.
doi:10.1371/journal.pone.0087180.g002

Levels of corticosterone are higher in mock-treated mice
than in vaccine-treated mice
The most striking change in this study was a 12-fold higher level
of corticosterone at day 8 p.i. in mock-treated DOG4-infected
mice versus uninfected controls, p,.001 (Figure 5A). Notably,
vaccine treatment completely eliminated the rise in brain
corticosterone associated with RABV infection. Corticosterone, a
stress hormone produced by the adrenal cortex, has been reported
to affect immune function and cellular metabolism and is
regulated in large part, by the hypothalamic-pituitary axis (HPA)
[24], which has been shown to be activated during RABV
infection [25,26]. Interestingly, at days 4 and 6 p.i, there were no
significant differences in brain corticosterone levels between mock
and vaccine treatment. It is possible that the surge in brain
corticosterone at day 8 of infection is associated with the dramatic
increase in virus replication in the hypothalamus and the adrenals
of mock-treated mice seen at this time point (Figures 1, S2). This
conclusion is further supported by the finding that the significantly
lower corticosterone levels in the TriGAS-treated mice correlate
with limited CNS infection at day 8 p.i. (Figure 1A–C).

Figure 3. Energy metabolites 3-hydroxybutyrate (BHBA) and
glucose increase in the CNS during the course of WT RABV
infection. Mice were infected i.n. with 105 FFU of DOG4 and 4 hr later
either mock treated i.m. with PBS or treated with 107 FFU of TriGAS. An
additional group of uninfected, untreated mice served as a reference.
Six mice per group were euthanized for each time point, and the levels
of BHBA and glucose were determined via LC-GC/MS-MS2 as described
in Materials and Methods. The results are presented as comparative
levels (+/2 SE). *p,.05, **p,.01.
doi:10.1371/journal.pone.0087180.g003

Indeed, we found serum corticosterone levels were significantly
elevated in mock-treated animals as early as 4 days p.i., and
continued to climb during the course of infection, reaching a
pinnacle by day 8 (Figure 5B). Importantly, vaccine treatment,
either by itself or with infection, caused no significant elevation in
serum corticosterone at any time during the study. To control for
stress effects induced from repeatedly bleeding each group of
animals, corticosterone was measured in uninfected, mock-treated
mice prior to treatment and at days 4, 6, and 8 afterwards.
Notably, corticosterone levels did not significantly differ at any any
time point in these uninfected mock-treated animals. These results
suggest that HPA activation occurs rapidly after RABV infection,

Serum corticosterone levels are elevated in mock-treated
mice early after RABV infection and continue to escalate
as the infection proceeds
Since corticosterone is produced in the periphery, we investigated whether serum levels of corticosterone were higher in
infected, mock-treated animals at earlier times than in brain tissue.
PLOS ONE | www.plosone.org
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Figure 4. Levels of carnitine and several acylcarnitines increase in the brains of TriGAS treated mice late in RABV infection. Mice
were infected i.n. with 105 FFU of DOG4 and 4 hr later either mock treated i.m. with PBS or treated with 107 FFU of TriGAS. An additional group of
uninfected, untreated mice served as a reference. Six mice per group were euthanized for each time point, and the levels of carnitine (A) and
acylcarnitines: hexanoylcarnitine (B), octanoylcarnitine (C), laurylcarnitine (D), palmitoylcarnitine (E), stearoylcarnitine (F), oleoylcarnitine (G), and
butyrylcarnitine (H) were determined via LC-GC/MS-MS2 as described in Materials and Methods. The results are presented as comparative levels (+/2
SE). *p,.05, **p,.01, ***p,.001.
doi:10.1371/journal.pone.0087180.g004

where corticosterone accumulates in the periphery and then enters
the CNS.

Post-exposure therapy with metyrapone, a
corticosterone synthesis inhibitor, reduces serum levels
of corticosterone in infected mice and attenuates the
pathogenicity of RABV
Dramatically elevated levels of brain and serum corticosterone
associated with RABV infection (Figure 5A–B) suggest that the
production of corticosterone and its widespread effects on both
immune function and cellular metabolism contribute to rabies
pathogenesis. To test this hypothesis, we investigated whether
treatment of RABV-infected mice i.p. with metyrapone, which
inhibits the conversion of 11-deoxycortisol to corticosterone in the
terminal reaction of the glucocorticoid biosynthetic pathway,
affects the outcome of the infection. Metyrapone significantly
attenuated the elevation in corticosterone associated with pathogenic RABV infection when administered each day for 21 days
(beginning 4 hours post-infection) (Figure 6). The discrepancy
between serum corticosterone levels of mock-treated DOG4infected mice at day 8 p.i. shown in Figures 5B and 6 is likely due
to the different challenge doses that were used in the two
experiments. While mice in Fig. 5B were challenged with 105 FFU
of DOG4, mice in Figure 6 were challenged with only 104 FFU of
DOG4 which likely resulted in a delay of the disease process and
thus a shift in the corticosterone production. Strikingly, metyrapone treatment ameliorated body weight loss and clinical signs
associated with infection, leading to significantly reduced mortality
(Figure 7A–C). Metyrapone treatment had no effect on virus
replication in the CNS over the first critical 8 days of infection
(Table S2). Furthermore, comparison of the induction of RABVspecific antibody in metyrapone versus mock-treated infected
animals over the first 8 days of infection (after which untreated
infection is terminal) revealed no significant differences between
the groups. However, the metyrapone-treated mice that survived
DOG4 infection had developed significant serum VNA titers by
day 12 p.i. (Table S3). The most likely explanation for the VNA
titer increase in metyrapone treated mice after day 8 p.i. is that in
the initial phase of the infection (up to day 8) the virus spread is
largely confined to the brain thereby preventing the induction of
antibody responses. During the later phase of the infection virus
spreads into peripheral tissues where an immune response can be
triggered.
Figure 5. Postexposure treatment of DOG4 RV-infected mice
with TriGAS prevents the elevation of corticosterone associated with pathogenic RABV in brain and serum. A) Mice were
infected i.n. with 105 FFU of DOG4 and 4 hr later either mock treated
with PBS or treated with 107 FFU of TriGAS. An additional group of
uninfected, untreated mice served as a reference. Six mice per group
were euthanized for each time point, and the levels of brain
corticosterone were determined via LC-GC/MS-MS2 as described in
Materials and Methods. B) Groups were identical to those in A), with
one additional group of animals receiving only TriGAS. Ten mice per
group were bled at each time point and serum corticosterone was
measured by EIA as described in Materials and Methods. The results
represent comparative levels of corticosterone (+/2 SE) *p,.05, **p,
.01, and ***p,.001, respectively.
doi:10.1371/journal.pone.0087180.g005

PLOS ONE | www.plosone.org

Discussion
Metabolome analysis of brain tissue from mock- and vaccinetreated RABV-infected mice was utilized to identify potentially
important biochemicals associated with lethal infection or
successful post-exposure prophylaxis with the live, highly attenuated RABV variant TriGAS. A similar approach has been used to
elucidate biochemicals and pathways contributing influenza- and
HIV-associated encephalopathies [27,28]. In addition, metabolomics have been recently utilized to characterize alterations in the
cerebral spinal fluid of human patients infected with rabies and in
the postmortem CNS tissues of an individual who succumbed to
6
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Figure 6. Post-exposure treatment of DOG4 RV-infected mice
with metyrapone blocks the rise in corticosterone associated
with pathogenic RABV. Mice were infected with 104 FFU of DOG4
RABV i.n. and either mock treated with PBS or treated with metyrapone
(100 mg/kg) i.p. each day for 21 days. Ten mice per group were bled
1 hr after injection for each time point. The results represent
comparative levels of corticosterone (+/2 SE). *p,.05, **p,.01, and
***p,.001, respectively.
doi:10.1371/journal.pone.0087180.g006

the disease [29,30]. The limitations of these studies are small
sample sizes, the assessment of a restricted number of metabolites
and the analysis being post mortem or limited to the late stages of
the disease. Using an animal model we were able to examine
changes in a large number of metabolites during the course of
lethal rabies infection and contrast these with metabolic changes
associated with a novel treatment modality.
Our study showed that levels of neurotransmitters, energy
metabolites and stress hormones were altered during the course of
WT RABV infection with the number of statistically significant
changes accumulating as viral load in the CNS increased (Table 1,
Figure 1A–C). This is consistent with reports demonstrating
manifold functional and structural changes in neurons infected
with rabies [31–33].
Notably, mock-treated animals displayed a marked reduction in
Ach levels during the course of infection (Figure 2), which likely
occurs via one or more mechanisms. The virus may be infecting
brain regions involved in Ach production, including structures of
the basal forebrain, or it may reduce the activity of choline
acetyltransferase, the enzyme involved in Ach synthesis. Alternatively, RABV may be changing the activity of the vesicular Ach
transporter affecting how the neurotransmitter is stored and
released or it may be increasing acetylcholinesterase activity,
promoting the degradation of Ach. Nevertheless, there is evidence
that the acetylcholine receptor interacts with RABV, facilitating
rabies virus entry into specific neurons [20,21]. Notably, Ach
neurotransmission is impaired in other encephalopathies (e.g.
Alzheimer’s, Parkinson’s) and acetylcholinesterase inhibitors which
restore levels of Ach provide therapeutic benefit, at least initially
[34]. If administered during rabies infection, such agents may
prove efficacious by either improving cholinergic signaling or by
promoting more effective competition between Ach and RABV at
PLOS ONE | www.plosone.org

Figure 7. PET with metyrapone, a corticosterone synthesis
inhibitor, reduces the pathogenicity of WT RABV. Groups of 20
mice were infected with 104 FFU of DOG4 RABV i.n. and either mocktreated with PBS or treated with metyrapone (100 mg/kg) i.p. each day
for 21 days. The mice were observed for 4 weeks, and body weight (A),
clinical signs (B) and survival (C) are presented (+/2 SE). For (A), twoway anova was used to determine significance effects in treatment per
day. (B) Two-way anova and Bonferroni post hoc tests were used to
indicate daily differences in clinical severity (*p,.05, **p,.01). (C) The
Mantel-Cox log-rank test was used to determine differences in
survivorship (*p,.05).
doi:10.1371/journal.pone.0087180.g007

the receptor level, thereby reducing viral entry and spread. In
support of this, it has been demonstrated that PET with
mecamylamine, a non-competitive acetylcholine receptor antagonist, reduces mortality in C57BL6 mice infected with a
moderately pathogenic strain of RABV [35].
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Cellular metabolism of amino acids assists in the formation of
neurotransmitters including Ach and our results suggest that rabies
is, in part, a disease of altered CNS metabolism. Significantly
elevated levels of glucose as well as the ketone body BHBA were
associated with later stages of RABV infection (Figure 3). Increases
in these important brain energy metabolites may signify decreased
usage or increased uptake by the RABV-infected brain as it
struggles to maintain cellular homeostasis in the face of a
continuously increasing viral load. The lack of a significance
difference in brain glucose levels between mock-treated, infected
and vaccine-treated, infected animals at day 8 p.i. is not surprising
as the mock-treated animals cease eating by this time and become
hypoglycemic (Figure S3). Our results support accumulating
evidence that rabies as well as many other CNS pathologies (e.g.
Alzheimer’s, Huntington’s, HIV encephalitis) can be considered
metabolic diseases as they result in progressive impairment of the
brain’s capacity to utilize glucose and/or insulin [36–38].
Importantly, alterations in brain energy metabolism associated
with RABV infection are fully ameliorated by vaccine treatment.
Our results suggest that therapeutic interventions which help
maintain metabolic function in the CNS (or conserve the rate of
glucose utilization) could also be beneficial. Perhaps this is why
induction of coma in humans infected with rabies decreases the
rate of mortality [39].
The largest change found in this study was dramatically higher
brain and serum corticosterone levels associated with infection in
the absence of PET or pharmacological intervention, with serum
levels increasing in infected animals before significant amounts of
virus became detectable in the brain and clinical signs of the
infection appeared (Figures 1, 5A–B, 7). The rise in corticosterone
is unlikely to be exclusively the result of a stress response to RABVmediated CNS damage because mock-treated mice exhibit no
clinical signs or weight loss at 4 and 6 days p.i. when serum
corticosterone levels are already elevated. It is more probable that
corticosterone blocks the induction of inflammatory processes that
promote immune cell activation, migration and infiltration into
the CNS. Glucocorticoids, including corticosterone, have potent
anti-inflammatory effects and reduce the expression of proinflammatory cytokines (TNF-alpha, IL-1), chemokines (CCL2,
CXCL10), prostaglandins (COX-2) and inducible nitric oxide
(iNOS) [40,41]. Glucocorticoids also interfere with the ability of
monocytes and dendritic cells to present antigen to T cells, reduce
immune cell proliferation and promote apoptosis in leukocytes and
T lymphocytes [42]. Moreover, it has been shown that glucocorticoid production after activation of the HPA axis can impair the
innate immune response, promoting the development of certain
infections [43]. In addition, several viruses including herpes
viruses, cytomegalovirus and New Castle disease virus have been
shown to activate the HPA axis [44]. Steroid hormones have been
demonstrated to reduce blood-brain barrier permeability and
immune effector infiltration into CNS tissues in mice infected with
attenuated RABV leading to increased mortality [17]. Similarly,
administration of corticosteroids has been shown to hasten the rate
of RABV mortality and morbidity in multiple animal species [25].
Humans infected with rabies display high levels of cortisol [45],
and elevated levels of this hormone, because of its early induction,
may serve as a biomarker for disease progression. Interestingly,
while treatment with metyrapone, an inhibitor of corticosterone
biosynthesis, prevented the increase in serum corticosterone levels
and reduced the pathogenicity of DOG4 infection (Figure 7A–C),
it did not reduce virus loads in the brain over the critical first 8
days of infection. Since the predominant effect of corticosteroids is
anti-inflammatory, we speculate that metyrapone promotes proinflammatory mechanisms, which have been shown to be
PLOS ONE | www.plosone.org

necessary for the antibody-mediated protection against a rabies
virus infection [46].
PET with TriGAS eliminated the large majority of neurological
abnormalities associated with WT RABV infection, including
alterations in levels of Ach, energy metabolites and corticosterone
(Figures 2, 3, 5A–B). TriGAS likely mediates these effects by
reducing viral replication levels in the CNS (Figure 1A–C) and by
promoting the rapid development of innate and adaptive
immunity [11,47]. Interestingly, carnitine and acylcarnitine
derivatives were significantly upregulated in treated compared to
mock-treated RABV-infected animals. Carnitines have been
shown to support immune function, supporting the production
of CD4+ and CD8+ T cells during infection [48,49]. Interestingly,
the time-dependent rise in carnitine levels shown in infected mice
that were administered TriGAS correlates with the development
of adaptive immunity, including extensive B and T cell infiltration
into the CNS at 8 days p.i. [47]. In addition to their
immunomodulatory effects, carnitines have been shown to
enhance Ach neurotransmission [50], preserve mitochondria
function [51] and promote lipid synthesis, all of which may be
mechanisms of neuroprotection [52].
In total, our results suggest that widespread metabolic changes,
including hypothalamic-pituitary-adrenal axis activation, are key
contributors to the pathogenicity of WT RABV and that
preventing these alterations early in infection with PET or
pharmacological blockade may help protect brain homeostasis
and allow for the development of the adaptive immune
mechanisms necessary to clear an otherwise lethal infection.

Materials and Methods
Viruses
The recombinant RABV SPBAANGAS-GAS-GAS (TriGAS)
was generated as described elsewhere [9] and propagated in BSR
cells, a derivative of BHK-21 cells [53]. The pathogenic WT
RABV strain DOG4 was propagated in NA cells (C1300 mouse
neuroblastoma, clone NA) as described previously [9]. To
determine virus titers, NA cells were grown for 2 days, and the
monolayers were infected with virus in 10-fold serial dilutions.
Forty-eight hours postinfection (p.i.), the cells were fixed with 80%
acetone and stained with fluorescein isothiocyanate (FITC)-labeled
RABV nucleoprotein (N)-specific antibody (Fujirebio Diagnostics,
Malvern, PA). Virus titers in triplicate samples were determined by
counting foci of infected cells using a fluorescence microscope and
are expressed as focus forming units (FFU) [54].

Real-time qPCR analysis to determine viral replication in
vivo
Eight- to 10-week-old female Swiss Webster mice were
purchased from Taconic Farms (Hudson, NY). To determine
viral spread of DOG4 in the CNS with and without TriGAS postexposure prophylaxis (PET), groups of 10–15 mice were inoculated intranasally (i.n.) with 20 ml containing 105 FFU of live
DOG4 and 4 hrs later, either mock-treated (PBS) or administered
with 107 FFU TriGAS in the masseter muscle (i.m.). At various
times later, mice were cardiac perfused, brain tissues were
removed, and total RNA was isolated using the RNeasy minikit
(Qiagen, Valencia, CA) according to the manufacturer’s instructions. For quantification of RABV N protein RNA, reverse
transcription (RT) and quantitative PCR (qPCR) were performed
as described previously [10,55]. Briefly, cDNA was synthesized by
reverse transcription using the IScript cDNA synthesis kit (BioRad). qPCR was performed on the iCycler iQ real-time detection
system (Bio-Rad) using iQ Supermix (Bio-Rad) with gene specific
8
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Plasma was stored at 280uC until assay. Corticosterone was
measured by corticosterone EIA (Arbor Assays, Ann Arbor, MI) in
duplicate according to manufacturer’s instructions.
All experiments with mice were conducted in accordance with
the Public Health Service Policy on Humane Care and Use of
Laboratory Animals under protocols approved by the Institutional
Animal Care and Use Committee of Thomas Jefferson University
(Animal Welfare Assurance no. A3085-01).

primers and probe for RABV N of DOG4, whose sequences have
been described previously [55]. RNA copy numbers for RABV N
were normalized to the copy numbers of the housekeeping gene
L13 in each sample as detailed elsewhere [56]. Statistical
significance of the differences between groups was determined
using the Mann-Whitney test.

Metabolome analysis of biomarkers associated with
rabies infection and post-infection viral clearance
facilitated by TriGAS treatment

Supporting Information

Two groups of 18 female C57BL/6 mice were infected i.n. with
105 FFU of DOG4. Four hours post infection, one group was
treated by intramuscular (i.m., masseter) injection of TriGAS
vaccine in PBS, the other group mock-treated with PBS vehicle.
An additional uninfected, untreated group served as a reference
for metabolic profiling. Global biochemical profiles of 259
biochemicals were determined in whole brain tissue samples taken
upon euthanasia at 4, 6 and 8 days post infection. Metabolic
profiling performed at Metabolon, Inc. (Research Triangle Park,
NC) combined three independent platforms: ultrahigh performance liquid chromatography/tandem mass spectrometry
(UHLC/MS/MS2) optimized for basic species, UHLC/MS/
MS2 optimized for acidic species, and gas chromatography/mass
spectrometry (GC/MS). Metabolites were identified by automated
comparison of the ion features in the experimental samples to a
reference library of chemical standard entries developed at
Metabolon. Following log transformation and imputation with
minimum observed values for each compound, Welch’s twosample t-tests were used to identify biochemicals that differed
significantly between 1) infected, mock-treated, 2) infected, vaccine
treated and in 3) healthy non-infected, non-treated mice at
respective time points.

Figure S1 Principal component analysis reveals changes in brain metabolism when comparing infected, mocktreated and infected, TriGAS-treated mice. Metabolites
cluster together according to time and treatment with the
exception of the day 8 samples, indicating an increasing number
of statistically significant differences between infected, mocktreated and infected, TriGAS-treated animals as the infection
progresses.
(TIF)
Figure S2 WT RABV infects the adrenal glands late in
infection. Mice were infected i.n. with 105 FFU of DOG4
RABV. Fifteen mice were euthanized and the number of DOG4
RABV N mRNA copies in both adrenal glands was quantified by
qRT-PCR as described in Materials and Methods. The results are
presented as the mean N mRNA copy numbers (+/2 SE) per
1,000 copies of L13 mRNA.
(TIF)
Figure S3 WT RABV results in hypoglycemia late in
infection. Groups of 10 C57BL/6 mice were bled 2 days prior to
infection, infected with 105 FFU of DOG4 RABV (closed bars) or
mock-infected with PBS (open bars) and bled 8 days later. Plasma
was separated and stored as described in Materials and Methods.
Blood glucose levels were measured using Nipro Diagnostics True
Track (Fort Lauderdale, FL) glucose meter, microchip #3614.
Values represent group means attained from pooling 5 ml serum
from each animal. Individual electronic strips were used for each
group. Intrastrip variability was ,5%, as determined by through
calibration.
(TIF)

WT RABV infection and PET treatment with metyrapone,
an 11-b hydroxylase inhibitor
To ensure metyrapone administration was not toxic in the
absence of infection, 20 C57BL6 mice were administered 100 or
200 mg/kg intraperitoneally (i.p.) daily for 21 days. Mice
displayed neither body weight loss nor overt clinical symptoms,
with the exception of 200 mg/kg causing temporary sedation. The
latter dose was not used in the subsequent experiments. Two
additional groups of 20 female C57BL6 mice were infected i.n.
with 104 FFU of DOG4. The lower dose of DOG4, which
consistently kills 90% of untreated animals, was chosen to better
enable the detection of any therapeutic effect. Four hours later,
mice were administered either metyrapone (100 mg/kg) or
phosphate-buffered saline (PBS) i.p. each day for 21 days. Mice
were observed daily for at least 28 days for clinical signs of rabies,
and body weights and survival were recorded. Moribund animals
were euthanized. Clinical signs were scored as follows: 1 = Disordered movement, piloerection; 2 = Hunched back, abnormal gait;
3 = Shaking/trembling, partial paralysis; 4 = Paralysis; 5 = Moribund/death.

Table S1 Time-dependent depiction and profile of

brain metabolic changes that may distinguish between
the progression and clearance of RABV infection. The
heat map shows metabolites differentially expressed in the brains
of a) DOG4-infected, mock-treated (Mock Treatment); b) DOG4infected, TriGAS-treated (Vaccine Treatment) and in c) healthy,
uninfected and untreated (Uninfected Control) mice at 4, 6 and 8
days p.i.
(DOCX)
Table S2 PET treatment with metyrapone has no effect
on WT RABV replication in the CNS over the first 8 days
of infection.
(DOCX)

Measurement of serum corticosterone

The metyrapone-treated mice that survived
WT RABV infection develop significant serum RABVspecific neutralizing antibodies (VNA) titers.
(DOCX)

Table S3

Eight 10 week old female C57BL/6 mice were briefly
anesthetized and bled using tail vein nick two days prior to i.n.
infection with 104 or 105 FFU of DOG4 or mock infection and
then after PBS or vaccine treatment (as described above) and on
days 4, 6, 8 and 10 p.i. To control for natural diurnal fluctuations
in levels of corticosterone, mice were bled between the hours of
9:00 am and 11:00 am each day. 25 ml serum from each animal
was placed on ice and then spun at 25006 g at 4uC for 20 min.
PLOS ONE | www.plosone.org

Author Contributions
Conceived and designed the experiments: BD KS MF. Performed the
experiments: KS CP MF. Analyzed the data: KS BD MF. Contributed

9

April 2014 | Volume 9 | Issue 4 | e87180

Metabolic Changes in Rabies Virus Pathogenesis

reagents/materials/analysis tools: BD DCH MF. Wrote the paper: KS BD
DCH MF.

References
1. Knobel DL, Cleaveland S, Coleman PG, Fevre EM, Meltzer MI, et al. (2005)
Re-evaluating the burden of rabies in Africa and Asia. Bull World Health Organ
83: 360–368.
2. Hampson K, Dushoff J, Cleaveland S, Haydon DT, Kaare M, et al. (2009)
Transmission dynamics and prospects for the elimination of canine rabies. PLoS
Biol 7: e53.
3. WHO (2004) WHO technical report series 931. Geneva, Switzerland.
4. Faber M, Dietzschold B, Li J (2009) Immunogenicity and safety of recombinant
rabies viruses used for oral vaccination of stray dogs and wildlife. Zoonoses
Public Health 56: 262–269.
5. Klingen Y, Conzelmann KK, Finke S (2008) Double-labeled rabies virus: live
tracking of enveloped virus transport. J Virol 82: 237–245.
6. Tsiang H (1979) Evidence for an intraaxonal transport of fixed and street rabies
virus. J Neuropathol Exp Neurol 38: 286–299.
7. Dietzschold B, Li J, Faber M, Schnell M (2008) Concepts in the pathogenesis of
rabies. Future Virol 3: 481–490.
8. Wilde H (2007) Failures of post-exposure rabies prophylaxis. Vaccine 25: 7605–
7609.
9. Faber M, Li J, Kean RB, Hooper DC, Alugupalli KR, et al. (2009) Effective
preexposure and postexposure prophylaxis of rabies with a highly attenuated
recombinant rabies virus. Proc Natl Acad Sci U S A 106: 11300–11305.
10. Li J, Ertel A, Portocarrero C, Barkhouse DA, Dietzschold B, et al. (2012)
Postexposure treatment with the live-attenuated rabies virus (RV) vaccine
TriGAS triggers the clearance of wild-type RV from the Central Nervous
System (CNS) through the rapid induction of genes relevant to adaptive
immunity in CNS tissues. J Virol 86: 3200–3210.
11. Schutsky K, Curtis D, Bongiorno EK, Barkhouse DA, Kean RB, et al. (2013)
Intramuscular Inoculation of Mice with the Live-Attenuated Recombinant
Rabies Virus TriGAS Results in a Transient Infection of the Draining Lymph
Nodes and a Robust, Long-Lasting Protective Immune Response against Rabies.
J Virol 87: 1834–1841.
12. Yan X, Prosniak M, Curtis MT, Weiss ML, Faber M, et al. (2001) Silver-haired
bat rabies virus variant does not induce apoptosis in the brain of experimentally
infected mice. J Neurovirol 7: 518–527.
13. Murphy FA (1977) Rabies pathogenesis. Arch Virol 54: 279–297.
14. Jackson AC, Rossiter JP (1997) Apoptosis plays an important role in
experimental rabies virus infection. J Virol 71: 5603–5607.
15. Fu ZF, Weihe E, Zheng YM, Schafer MK, Sheng H, et al. (1993) Differential
effects of rabies and borna disease viruses on immediate-early- and late-response
gene expression in brain tissues. J Virol 67: 6674–6681.
16. Roy A, Hooper DC (2008) Immune evasion by rabies viruses through the
maintenance of blood-brain barrier integrity. J Neurovirol 14: 401–411.
17. Roy A, Phares TW, Koprowski H, Hooper DC (2007) Failure to open the bloodbrain barrier and deliver immune effectors to central nervous system tissues leads
to the lethal outcome of silver-haired bat rabies virus infection. J Virol 81: 1110–
1118.
18. Shah SH, Kraus WE, Newgard CB (2012) Metabolomic profiling for the
identification of novel biomarkers and mechanisms related to common
cardiovascular diseases: form and function. Circulation 126: 1110–1120.
19. Xu XH, Huang Y, Wang G, Chen SD (2012) Metabolomics: a novel approach
to identify potential diagnostic biomarkers and pathogenesis in Alzheimer’s
disease. Neurosci Bull 28: 641–648.
20. Lafon M (2005) Rabies virus receptors. J Neurovirol 11: 82–87.
21. Lentz TL, Burrage TG, Smith AL, Tignor GH (1983) The acetylcholine
receptor as a cellular receptor for rabies virus. Yale J Biol Med 56: 315–322.
22. Osio M, Muscia F, Zampini L, Nascimbene C, Mailland E, et al. (2006) Acetyl-lcarnitine in the treatment of painful antiretroviral toxic neuropathy in human
immunodeficiency virus patients: an open label study. J Peripher Nerv Syst 11:
72–76.
23. Malaguarnera M, Gargante MP, Cristaldi E, Vacante M, Risino C, et al. (2008)
Acetyl-L-carnitine treatment in minimal hepatic encephalopathy. Dig Dis Sci
53: 3018–3025.
24. Silverman MN, Sternberg EM (2012) Glucocorticoid regulation of inflammation
and its functional correlates: from HPA axis to glucocorticoid receptor
dysfunction. Ann N Y Acad Sci 1261: 55–63.
25. Enright JB, Goggin JE, Frye FL, Franti CE, Behymer DE (1970) Effects of
corticosteroids on rabies virus infections in various animal species. J Am Vet
Med Assoc 156: 765–769.
26. Roy A, Hooper DC (2007) Lethal silver-haired bat rabies virus infection can be
prevented by opening the blood-brain barrier. J Virol 81: 7993–7998.
27. Wikoff WR, Pendyala G, Siuzdak G, Fox HS (2008) Metabolomic analysis of the
cerebrospinal fluid reveals changes in phospholipase expression in the CNS of
SIV-infected macaques. J Clin Invest 118: 2661–2669.
28. Kawashima H, Oguchi M, Ioi H, Amaha M, Yamanaka G, et al. (2006) Primary
biomarkers in cerebral spinal fluid obtained from patients with influenzaassociated encephalopathy analyzed by metabolomics. Int J Neurosci 116: 927–
936.

PLOS ONE | www.plosone.org

29. Reinke SN, Resch L, Maingat F, Branton W, Jackson AC, et al. (2013)
Metagenomic and metabolomic characterization of rabies encephalitis: new
insights into the treatment of an ancient disease. J Infect Dis 207: 1451–1456.
30. O’Sullivan A, Willoughby RE, Mishchuk D, Alcarraz B, Cabezas-Sanchez C,
et al. (2013) Metabolomics of cerebrospinal fluid from humans treated for rabies.
J Proteome Res 12: 481–490.
31. Fu ZF, Li X, Dhingra V (2008) Pathogenic rabies virus alters host protein
expression in the central nervous system: implications for neuronal dysfunction.
Dev Biol (Basel) 131: 83–91.
32. Dhingra V, Li X, Liu Y, Fu ZF (2007) Proteomic profiling reveals that rabies
virus infection results in differential expression of host proteins involved in ion
homeostasis and synaptic physiology in the central nervous system. J Neurovirol
13: 107–117.
33. Scott CA, Rossiter JP, Andrew RD, Jackson AC (2008) Structural abnormalities
in neurons are sufficient to explain the clinical disease and fatal outcome of
experimental rabies in yellow fluorescent protein-expressing transgenic mice.
J Virol 82: 513–521.
34. Kawamata J, Shimohama S (2011) Stimulating nicotinic receptors trigger
multiple pathways attenuating cytotoxicity in models of Alzheimer’s and
Parkinson’s diseases. J Alzheimers Dis 24 Suppl 2: 95–109.
35. Chopy DM, Lafon M (2012) USE OF MECAMYLAMINE IN THE
TREATMENT OF PATHOGEN-INFECTED PATIENTS WITH CENTRAL NERVOUS SYSTEM DISORDER. Patent Application No: PCT/
EP2012/061536, Publication Date: 20.12.2012; www.wipo.int
36. Beliakov NA, Medvedev SV, Trofimova TN, Rassokhin VV, Dement’eva NE,
et al. (2012) [Mechanisms of cerebral damage in patients with HIV-infection].
Vestn Ross Akad Med Nauk: 4–12.
37. Olah J, Klivenyi P, Gardian G, Vecsei L, Orosz F, et al. (2008) Increased glucose
metabolism and ATP level in brain tissue of Huntington’s disease transgenic
mice. FEBS J 275: 4740–4755.
38. de la Monte SM (2012) Contributions of brain insulin resistance and deficiency
in amyloid-related neurodegeneration in Alzheimer’s disease. Drugs 72: 49–66.
39. Jackson AC (2011) Rabies in the critical care unit: diagnostic and therapeutic
approaches. Can J Neurol Sci 38: 689–695.
40. Szabo C, Thiemermann C, Wu CC, Perretti M, Vane JR (1994) Attenuation of
the induction of nitric oxide synthase by endogenous glucocorticoids accounts
for endotoxin tolerance in vivo. Proc Natl Acad Sci U S A 91: 271–275.
41. Tait AS, Butts CL, Sternberg EM (2008) The role of glucocorticoids and
progestins in inflammatory, autoimmune, and infectious disease. J Leukoc Biol
84: 924–931.
42. Smets LA, Salomons G, van den Berg J (1999) Glucocorticoid induced apoptosis
in leukemia. Adv Exp Med Biol 457: 607–614.
43. Jamieson AM, Yu S, Annicelli CH, Medzhitov R (2010) Influenza virus-induced
glucocorticoids compromise innate host defense against a secondary bacterial
infection. Cell Host Microbe 7: 103–114.
44. Silverman MN, Pearce BD, Biron CA, Miller AH (2005) Immune modulation of
the hypothalamic-pituitary-adrenal (HPA) axis during viral infection. Viral
Immunol 18: 41–78.
45. Hemachudha T (1994) Human rabies: clinical aspects, pathogenesis, and
potential therapy. Curr Top Microbiol Immunol 187: 121–143.
46. Hooper DC, Morimoto K, Bette M, Weihe E, Koprowski H, Dietzschold B
(1998) Collaboration of antibody and inflammation in clearance of rabies virus
from the central nervous system. J Virol 72: 3711–3719
47. Li J, Faber M, Dietzschold B, Hooper DC (2011) The role of toll-like receptors
in the induction of immune responses during rabies virus infection. Adv Virus
Res 79: 115–126.
48. Jirillo E, Altamura M, Marcuccio C, Tortorella C, De Simone C, et al. (1993)
Immunological responses in patients with tuberculosis and in vivo effects of
acetyl-L-carnitine oral administration. Mediators Inflamm 2: S17–20.
49. De Simone C, Ferrari M, Lozzi A, Meli D, Ricca D, et al. (1982) Vitamins and
immunity: II. Influence of L-carnitine on the immune system. Acta Vitaminol
Enzymol 4: 135–140.
50. Janiri L, Falcone M, Persico A, Tempesta E (1991) Activity of L-carnitine and Lacetylcarnitine on cholinoceptive neocortical neurons of the rat in vivo. J Neural
Transm Gen Sect 86: 135–146.
51. Marcovina SM, Sirtori C, Peracino A, Gheorghiade M, Borum P, et al. (2013)
Translating the basic knowledge of mitochondrial functions to metabolic
therapy: role of L-carnitine. Transl Res 161: 73–84.
52. Jones LL, McDonald DA, Borum PR (2010) Acylcarnitines: role in brain. Prog
Lipid Res 49: 61–75.
53. Sato M, Maeda N, Yoshida H, Urade M, Saito S (1977) Plaque formation of
herpes virus hominis type 2 and rubella virus in variants isolated from the
colonies of BHK21/WI-2 cells formed in soft agar. Arch Virol 53: 269–273.
54. Faber M, Faber ML, Papaneri A, Bette M, Weihe E, et al. (2005) A single amino
acid change in rabies virus glycoprotein increases virus spread and enhances
virus pathogenicity. J Virol 79: 14141–14148.

10

April 2014 | Volume 9 | Issue 4 | e87180

Metabolic Changes in Rabies Virus Pathogenesis

56. Phares TW, Kean RB, Mikheeva T, Hooper DC (2006) Regional differences in
blood-brain barrier permeability changes and inflammation in the apathogenic
clearance of virus from the central nervous system. J Immunol 176: 7666–7675.

55. Faber M, Faber ML, Li J, Preuss MA, Schnell MJ, et al. (2007) Dominance of a
nonpathogenic glycoprotein gene over a pathogenic glycoprotein gene in rabies
virus. J Virol 81: 7041–7047.

PLOS ONE | www.plosone.org

11

April 2014 | Volume 9 | Issue 4 | e87180

